JNJ-75348780
Sponsors
Janssen-Cilag International NV, Yoshinari Nozomi, Janssen Research & Development, LLC
Conditions
Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLeukemia, Myeloid, Acute
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-HodgkinLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsNon-Hodgkin lymphoma and chronic lymphocytic leukemia
CancerProstatic Neoplasms, Castration-Resistant
Phase 1
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
CompletedNCT04540796
Start: 2020-11-20End: 2025-09-09Updated: 2025-10-10
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Active, not recruitingNCT06139406
Start: 2023-12-06End: 2026-08-31Updated: 2026-07-06
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Active, not recruitingNCT06660563
Start: 2024-10-22End: 2027-03-31Updated: 2026-07-06
A rollover study for continued study treatment and ongoing safety monitoring
RecruitingISRCTN87946208
Start: 2024-12-31Target: 77Updated: 2025-03-31
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Enrolling by invitationNCT06788509
Start: 2024-12-30End: 2028-10-30Target: 120Updated: 2026-07-06
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Active, not recruitingJPRN-jRCT2041240191
Start: 2025-02-19Target: 80Updated: 2026-06-29